Adage Capital Partners’s Revolution Medicines RVMD Stock Holding History

Adage Capital Partners’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$112M	Sell	597,226 -4,878,385	-89%	-$713M	0.16%	121
2026 Q1	$533M	Buy	5,475,611 +3,270,056	+148%	+$330M	0.82%	15
2025 Q4	$176M	Buy	2,205,555 +1,463,155	+197%	+$95.9M	0.27%	65
2025 Q3	$34.7M	Buy	742,400 +345,000	+87%	+$13.5M	0.05%	320
2025 Q2	$14.6M	Buy	397,400 +3,400	+0.9%	+$131K	0.02%	522
2025 Q1	$13.9M	Sell	394,000 -256,000	-39%	-$10.4M	0.03%	504
2024 Q4	$28.4M	Buy	650,000 +360,000	+124%	+$18.2M	0.05%	346
2024 Q3	$13.2M	Buy	290,000 +120,000	+71%	+$5.23M	0.02%	557
2024 Q2	$6.6M	Sell	170,000 -30,000	-15%	-$1.12M	0.01%	677
2024 Q1	$6.45M	Buy	+200,000	New	+$5.93M	0.01%	668
2023 Q4	–	Sell	-30,000	Closed	-$830K	–	920
2023 Q3	$830K	Buy	+30,000	New	+$890K	﹤0.01%	770
2020 Q2	–	Sell	-25,000	Closed	-$548K	–	793
2020 Q1	$548K	Buy	+25,000	New	+$692K	﹤0.01%	698

Other funds holding RVMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Adage Capital Partners's RVMD Position: Q2 2026 in Review

Adage Capital Partners reduced its Revolution Medicines (RVMD) stake by 89% in Q2 2026, selling an estimated $713M and leaving 597,226 shares worth $112M. The position accounts for 0.16% of the portfolio, ranked #121.

Adage Capital Partners first reported a position in RVMD in Q1 2020 and has held it in 12 quarters since. The position peaked at $533M in Q1 2026. 691 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

Adage Capital Partners held 597,226 shares of Revolution Medicines worth $112M as of Q2 2026.
Adage Capital Partners sold 4,878,385 Revolution Medicines shares in Q2 2026, an estimated $713M.
Revolution Medicines made up 0.16% of Adage Capital Partners's portfolio in Q2 2026, its #121 holding.
Adage Capital Partners first reported a position in Revolution Medicines in Q1 2020 and has held it in 12 quarters since.
Adage Capital Partners's Revolution Medicines position peaked at $533M in Q1 2026.
691 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.